[Phage-display technology and its application to experimental oncological therapy]

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Context:

• Selective drug delivery to cancer cells and tumor vasculature is a major challenge in oncology.
• Peptide-based targeting ligands offer a strategy to enhance drug specificity.
• Phage display is a key technology for identifying and developing these targeting peptides.

Purpose:

• To explore the application of phage display technology in developing targeted cancer therapies.
• To highlight the potential of phage-derived peptides and antibodies in oncology.
• To discuss the mechanisms by which these molecules exert anti-cancer effects.

Summary:

• Phage display technology is instrumental in generating peptides that bind specifically to cancer cells and tumor endothelial cells.
• These peptides can inhibit angiogenesis, reduce metastasis, and block enzymes crucial for cancer progression.
• The technology also facilitates the development of anti-cancer recombinant antibodies, such as single-chain variable fragments (scFv), for therapeutic applications.
• Modified scFv molecules can exhibit enhanced affinity and avidity, and can be conjugated with effector molecules to induce anti-cancer functions.

Impact:

• Phage display provides a powerful platform for discovering novel anti-cancer agents.
• Targeted delivery using phage-derived molecules can improve the efficacy and reduce the side effects of cancer treatments.
• This technology contributes to the development of advanced cancer vaccines and drug delivery systems.